Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document· April 28, 2026

Is Novo Nordisk (CPSE:NOVO B) Pricing Reflect Its Recent Share Price Swings And Growth Outlook

View original at finance.yahoo.com

Is Novo Nordisk (CPSE:NOVO B) Pricing Reflect Its Recent Share Price Swings And Growth Outlook Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE…

Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

237 more high quality undervalued stocks are identified on Simply Wall St's platform
60% confidence
Sell-side analysts have provided explicit Free Cash Flow forecasts for Novo Nordisk out to 2030, with Simply Wall St extrapolating further to 2035
60% confidence
Novo Nordisk projected Free Cash Flow reaches DKK 107.4 billion by 2030
60% confidence
Novo Nordisk's 34.5% return over the last year is lagging behind its pharmaceutical peers
60% confidence
Novo Nordisk is undervalued by 65.4% based on DCF analysis, with an intrinsic value of DKK 769.11 per share
60% confidence
Novo Nordisk extrapolated Free Cash Flow reaches approximately DKK 145.9 billion by 2035
60% confidence
Investors have been reassessing Novo Nordisk's growth expectations and risk, shifting sentiment and explaining the mix of short-term gains and long-term declines
60% confidence
Novo Nordisk scores 5 out of 6 on Simply Wall St's valuation checks
60% confidence

Data points we hold from this source

Novo Nordisk · free cash flow	52.1 billion_DKK
Novo Nordisk · free cash flow projected	107.4 billion_DKK
Novo Nordisk · free cash flow extrapolated	145.9 billion_DKK
Novo Nordisk · dcf intrinsic value	769.11 DKK_per_share
Novo Nordisk · discount to intrinsic value	65.4 percent